Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case–control study, Spain, 2023/24 season

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.5.2400596?emailalert=true&utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz--Xbkrqce5pLuwqMqDhm3QHGFCPLh7DvHIZ1bcqbjTIvw7aAPv4cR3FEokH5Tq-lEgQfnhUn5s_oM6vMegIl1SHFztrnA&_hsmi=346170968&utm_content=346170968&utm_source=hs_email A test of RSV antibodies in Spanish babies New data from Spain show Beyfortus, the antibody injection that protects babies from RSV, was highly protective there during the first year of its rollout. Spain was one of the first countries to offer all babies the injection during their first RSV season. A case-control study showed that the injection was 80% effective at preventing hospitalizations for RSV in inoculated children when compared to kids who didn’t get the shot. There was a similar effectiveness for more serious outcomes from RSV infection — ICU admissions and the need for mechanical ventilation. The effectiveness of the long-acting monoclonal antibody, nirsevimab, “together with its high coverage in Spain, have resulted in a substantial impact,” and bodes well for similar campaigns in upcoming seasons, the researchers wrote in the online journal Eurosurveillance. Beyfortus is marketed by Sanofi and AstraZeneca. — Helen Branswell